转自:国家医保局官微 编辑:水晶3月9日,国家医疗保障局办公室发布通知,鉴于和黄医药(中国)有限公司已启动其授权引进产品“氢溴酸他泽司他片”(商品名:达唯珂)的撤市及召回程序,自2026年3月9日起,决定采取撤销挂网和移出目录的通知。3月9日,和黄医药(中国)有限公司发布公告,宣布对其授权引进产品氢溴酸他泽司他片(商品名:达唯珂)启动主动召回及全球撤市程序。核心原因:在该药物正在进行的全球Ib/...
Source Link转自:国家医保局官微 编辑:水晶3月9日,国家医疗保障局办公室发布通知,鉴于和黄医药(中国)有限公司已启动其授权引进产品“氢溴酸他泽司他片”(商品名:达唯珂)的撤市及召回程序,自2026年3月9日起,决定采取撤销挂网和移出目录的通知。3月9日,和黄医药(中国)有限公司发布公告,宣布对其授权引进产品氢溴酸他泽司他片(商品名:达唯珂)启动主动召回及全球撤市程序。核心原因:在该药物正在进行的全球Ib/...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.